COMP <GO>
NPO vs TMO // EV/EBITDA & P/E VALUATION
Enpro Inc. (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: NPO 5
— TMO 9
▲ EV/EBITDA & P/E VALUATION LEADER: TMO
LAST: $271.53 (-4.54%) • MKT CAP: $6.02B
valuation
33.3x
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
valuation
30.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NPO VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NPO | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 42.60% | 41.00% | +1.60 | NPO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 6.10% | 9.30% | -3.20 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 33.3x | 30.4x | +2.90 | TMO | /valuation <GO> |
| Free Cash Flow Yield | 0.07% | 2.40% | -2.33 | TMO | /fcf-yield <GO> |
| Operating Margin | 14.10% | 17.40% | -3.30 | TMO | /operating-margins <GO> |
| Net Profit Margin | 3.50% | 15.10% | -11.60 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 9.00% | 3.90% | +5.10 | NPO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.44% | 0.24% | +0.20 | NPO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.60 | 4.50 | +0.10 | NPO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 6.70% | -0.20 | NPO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 37.8 | 59.1 | -21.35 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.87 | 0.94 | -0.07 | TMO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 138.3x | 36.3x | +102.00 | TMO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $6.02B | $262.22B | -$256.20B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NPO REV | TMO REV | NPO GROSS % | TMO GROSS % | NPO FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.14B | $44.56B | 42.6% | 44.0% | $3.4M | $6.29B |
| FY 2024 | $1.05B | $42.88B | 42.4% | 44.0% | $52.5M | $7.27B |
| FY 2023 | $1.06B | $42.86B | 44.0% | 44.0% | -$22.8M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NPO // BETA 0.87
TMO // BETA 0.94